NCT00649077

Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

Single-Dose Fasting In Vivo Bioequivalence Study of Meloxicam Tablets (15 mg; Mylan) and Mobic® Tablets (15 mg; Boehringer Ingelheim) in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Mylan Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x 15 mg) dose administration under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Meloxicam Tablets 15 mg	15mg, single dose fasting
DRUG	Mobic® Tablets 15 mg	15mg, single dose fasting

Timeline

• Start date: 2004-08-01
• Primary completion: 2004-09-01
• Completion: 2004-09-01
• First posted: 2008-04-01
• Last updated: 2024-04-24

Locations

1 site across 1 country: United States